An Act Regarding Coverage for Step Therapy for Metastatic Cancer
Summary
LD 178 creates a new insurance coverage rule for prescription drugs used to treat metastatic cancer and the associated conditions that can accompany the disease or its treatment. It defines “metastatic cancer” and “associated conditions,” with the latter covering symptoms or side effects that, in a health care practitioner’s judgment, could further jeopardize a patient’s health if left untreated.
The bill prohibits a carrier or utilization review organization from requiring step therapy before covering an FDA-approved prescription drug for metastatic cancer or associated conditions when that drug is on the plan’s formulary. In practical terms, this means patients with metastatic cancer would not have to try less expensive or preferred medications first before gaining access to the prescribed treatment. The law applies to health plans issued or renewed on or after January 1, 2026.
Impact
The bill amends Maine’s insurance code, specifically 24-A MRSA §4320-N, by adding definitions and a new exception to step therapy requirements for metastatic cancer treatment. It affects health carriers and utilization review organizations by limiting their ability to impose step therapy protocols for FDA-approved drugs used in this context. The fiscal note indicates modest state costs to implement the expanded requirements, with funding allocated in the General Fund and Highway Fund for 2026-27.
Sentiment
The available record shows no committee transcript or recorded votes, so there is no documented debate or roll-call sentiment in the provided materials. Based on the bill’s subject matter and enacted status, the measure appears to have been treated as a patient-access and cancer-care protection bill rather than a controversial policy change. The governor approved it on July 1, 2025, indicating final executive support.
Contention
No specific points of contention are documented in the provided materials. In general, bills limiting step therapy can raise concerns from insurers and utilization review organizations about cost control and formulary management, while patient advocates and clinicians typically support faster access to medically necessary treatment. Here, the statute’s focus on metastatic cancer and associated conditions suggests the principal policy balance is between insurer utilization controls and timely access to oncology medications.